Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ambiq Micro Q4 2025 Earnings Call - Management Sees Path to >$100M in 2026 Backed by Apollo5 Momentum and Atomic Roadmap
Ambiq closed 2025 with its strongest quarter and a sharpened focus on Edge AI. Q4 net sales beat guidance as customers accelerated orders, driven by broader adoption of Apollo5 and new product ramps. ...
- Q4 2025 net sales were $20.7 million, up 2% year-over-year, and above company guidance.
- Q4 non-GAAP gross profit was $9.4 million, with a non-GAAP gross margin of 45.5%, roughly 20 percentage points higher year-over-year.
- Full-year 2025 gross profit dollars rose 32.1% despite net sales being down 4.7% year-over-year, validating the company’s strategic repositioning.
- +12 more takeaways
NCS Multistage Fourth Quarter and Full Year 2025 Earnings Call - ResMetrics deal boosts diagnostics, >70% EBITDA-to-cash conversion
NCS Multistage closed 2025 with solid top-line gains and an unusually high cash conversion rate. Full-year revenue rose 13% to $183.6 million (10% ex-ResMetrics), adjusted EBITDA jumped 20% to $26.7 m...
- Full-year 2025 revenue $183.6 million, up 13% year-over-year, and up 10% excluding the ResMetrics acquisition completed July 31, 2025.
- Adjusted EBITDA for 2025 rose 20% to $26.7 million, with management citing expanded operating leverage and product mix improvements.
- Free cash flow after distributions to non-controlling interests was about $19 million in 2025, implying more than 70% conversion of adjusted EBITDA, a standout metric for an asset-light business.
- +13 more takeaways
Capital Clean Energy Carriers Corp. Q4 2025 Earnings Call - Aggressive gas pivot, 3 new LNG high-tech orders and a geopolitically driven spike in spot rates
Capital Clean Energy Carriers used Q4 to double down on its pivot from containers to gas, contracting three latest-technology LNG carriers and delivering the industry first 22,000 cbm liquid CO2 multi...
- Contracted three latest-technology LNG carriers at HD Hyundai Samho, deliveries scheduled one in Q4 2028 and two in Q1 2029, designed for higher fuel efficiency, lower boil-off and enhanced liquefaction capacity.
- Delivered the Active, the world’s first 22,000 cbm liquid CO2 multi-gas carrier, now employed on a six-month LPG charter with an option to extend, demonstrating immediate commercial demand.
- Company has sold 14 container vessels in 24 months, leaving one container vessel on a long-term charter to 2033 with extension options to 2039, management will only sell if accretive.
- +12 more takeaways
NACCO Industries Fourth Quarter 2025 Earnings Call - 59% Adjusted EBITDA Lift, Pension Settlement Produces Net Loss
NACCO closed 2025 with a clear operational rebound, reporting consolidated Adjusted EBITDA up 59% year over year to $14.3 million and consolidated gross profit rising 42% to $12 million on revenue of ...
- Adjusted EBITDA jumped 59% year over year to $14.3 million in Q4 2025, signaling a strong operational recovery across the company.
- Consolidated gross profit rose 42% year over year to $12.0 million, while revenues increased only 5% to $66.8 million, showing margin-driven improvement.
- GAAP net loss of $3.8 million in Q4 was driven by a $7.8 million non-cash pension settlement charge, $6.0 million after tax, plus a full-year tax true-up.
- +12 more takeaways
Aquestive Therapeutics Q4 2025 Earnings Call - Targets Q3 2026 NDA Resubmission for Anaphylm After FDA Type A Request
Aquestive presented a confident, operationally focused update: management has requested a Type A meeting with the FDA (expected within ~30 days), selected CROs and drafted protocols for the two studie...
- Aquestive has submitted a Type A meeting request to the FDA and expects the meeting within ~30 days, following the CRL focused on human factors and a PK study.
- Management is guiding a resubmission of the Anaphylm NDA in Q3 2026, saying they have a "clear and achievable" path to satisfy FDA requests.
- The company has selected CROs and drafted protocols for the two FDA-requested studies, the human factors validation study and a PK study, and is already preparing for dosing.
- +13 more takeaways
CorMedix Q4 2025 Earnings Call - DefenCath guidance affirmed as TDAPA shifts to bundled add-on, REZZAYO Phase 3 readout set for Q2 2026
CorMedix closed a transformational 2025: the Melinta acquisition closed in August, management achieved the targeted $35 million of synergies in Q4, and full-year pro forma revenue reached $401.3 milli...
- CorMedix closed Melinta acquisition in August 2025 and achieved targeted synergies of $35 million during Q4 2025.
- Pro forma full-year 2025 revenue was $401.3 million, in line with prior guidance.
- Q4 2025 net revenue was $128.6 million, with DefenCath contributing $91.2 million and the Melinta portfolio $37.4 million.
- +17 more takeaways
Myers Industries Q4 2025 Earnings Call - Transformation and MTS Divestiture Drive Margin Expansion and FCF Recovery
Myers pitched 2025 as an inflection year. Management executed a focused transformation, exited low‑margin lines and idled two of nine rotational molding facilities, and announced the strategic decisio...
- Q4 net sales were $204.0 million, essentially flat year over year; full year 2025 net sales were $825.7 million, down 1.3% versus 2024.
- Management completed a strategic review and announced the decision to sell Myers Tire Supply, with MTS expected to be treated as discontinued operations beginning in Q1 2026, which will alter future comparability and outlooks for automotive aftermarket exposure.
- Adjusted gross margin in Q4 expanded 140 basis points to 33.6%, and adjusted operating margin widened 230 basis points to 11.0%, reflecting favorable mix, higher volume, and focused transformation savings.
- +11 more takeaways
flyExclusive Q4 2025 Earnings Call - First Positive Adjusted EBITDA as Fleet Reset Drives Structural Profitability
flyExclusive says 2025 was a turning point. The company removed non-performing aircraft, modernized the fleet, and tightened execution, producing a 15% revenue gain to $375.9 million, a 53% jump in gr...
- Q4 2025 Adjusted EBITDA turned positive at $6.6 million, representing a 6% Adjusted EBITDA margin, the first positive quarter since going public.
- Full year 2025 revenue was $375.9 million, up 15% year-over-year, with Q4 revenue of $104.3 million, up 14% year-over-year.
- Fly hours increased roughly 12% for the year to about 75,000, and Q4 flight hours rose about 13% to ~20,400 hours, even with a fleet 14% smaller versus 2024.
- +14 more takeaways
Lightwave Logic Q4 and Full Year 2025 Earnings Call - Foundry integrations deepen; 2027 earliest production ramp
Lightwave Logic spent 2025 moving from lab validation toward foundry-ready commercialization. The company reports material progress on its Perkinamine electro-optic polymer platform, deeper reliabilit...
- Perkinamine polymer platform showed meaningful execution progress in 2025, with improved reliability data addressing temperature stability and photo-oxidation concerns from prior generations.
- Three customer programs reached stage 3 (prototype to final product) in 2025, and Lightwave Logic added a fourth Fortune Global 500 customer in early 2026; roughly 15 additional engagements are in stage 1 or 2.
- Company expects 2026 revenue to be driven primarily by material supply and non‑recurring engineering work; volume production and licensing revenues are not anticipated until 2027 at the earliest.
- +11 more takeaways
Palladyne AI Q4 2025 Earnings Call - Reiterated $24M-$27M 2026 Guidance as Vertical Integration Starts to Drive Backlog
Palladyne AI told investors it has moved from a development-stage AI shop to a vertically integrated industrial and defense platform after three November acquisitions, and is reiterating 2026 revenue ...
- Reiterated 2026 revenue guidance of $24 million to $27 million, roughly 4x–5x 2025 revenue, and management expects organic growth plus M&A contribution across AI, UAV, and manufacturing segments.
- Backlog rose from about $13.5 million at 12/31/2025 to nearly $18 million midway through Q1 2026, reflecting new contract wins net of invoicing activity.
- Q4 2025 revenue was $1.7 million, up 118% year-over-year, but that included approximately six weeks of contribution from the November acquisitions.
- +12 more takeaways